Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial

OBJECTIVES: To characterise infections in patients with rheumatoid arthritis (RA) in ORAL Surveillance. METHODS: In this open-label, randomised controlled trial, patients with RA aged≥50 years with ≥1 additional cardiovascular risk factor received tofacitinib 5 or 10 mg two times per day or a tumour...

Descripción completa

Detalles Bibliográficos
Autores principales: Balanescu, Andra-Rodica, Citera, Gustavo, Pascual-Ramos, Virginia, Bhatt, Deepak L, Connell, Carol A, Gold, David, Chen, All-Shine, Sawyerr, Gosford, Shapiro, Andrea B, Pope, Janet E, Schulze-Koops, Hendrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606533/
https://www.ncbi.nlm.nih.gov/pubmed/35922124
http://dx.doi.org/10.1136/ard-2022-222405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606533/
https://www.ncbi.nlm.nih.gov/pubmed/35922124
http://dx.doi.org/10.1136/ard-2022-222405

Ejemplares similares